YAMANE Akio Institution for Medical Research, Wakunaga Pharmaceutical Co., Ltd., Associate Director, 創薬研究所, 副所長(研究職)
JUJI Takeo Central Blood Center, The Japanese Red Cross, Director, 中央血液センター, 所長(研究職)
TSUCHIYA Naoyuki Graduate School of Medicine, University of Tokyo, Associate Professor, 医学系研究科, 助教授 (60231437)
|Budget Amount *help
¥11,900,000 (Direct Cost: ¥11,900,000)
Fiscal Year 1999: ¥2,100,000 (Direct Cost: ¥2,100,000)
Fiscal Year 1998: ¥2,800,000 (Direct Cost: ¥2,800,000)
Fiscal Year 1997: ¥7,000,000 (Direct Cost: ¥7,000,000)
1. Screening of variations at HLA-A, -B, and -C loci followed by nucleotide sequencing elucidated a number of new alleles including HLA-B22, -B27, -Cw2, and several non-expressed (null) alleles. Consequently, we could identify most, if not all, of the HLA class I alleles existing in the Japanese population.
2. DNA-based typing kits for HLA-A and -B loci at the intermediate resolution were established using the PCR-MPH method. Also, DNA-based typing kits for HLA-C locus as well as -A2, -A26, -B15, and -B40 groups at the sequence-level resolution were established using the PCR-MPH method. Thus, most of the HLA class I alleles in Japanese can be detected using these PCR-MPH kits. In addition, DNA-based typing methods for HLA-A and B loci at the sequence-level resolution, suitable for small number of samples, were established using the PCR-RFLP method.
3. Using the above methods, we performed sequence-level typing for HLA-A, B, and C loci in Japanese population samples, and reported allele and haplotype frequenecies. Moreover, we investigated the diversity of alleles and haplotypes of HLA-B61 and -B17 groups in East Asian populations.